Influenza is one of the most common diseases in the world that caused many pandemics.
Influenza season and pathogenic:
Influenza usually common during fall and winter, especially during October and March. Most of the time flu activity peaks in February, according to CDC. The three types of Influenza viruses A, B, C, are responsible for seasonal flu epidemics each year the most dangerous is type A because it affects both humans and animals and is divided into subtypes.
Common signs and symptoms of the influenza include Sore throat, dry cough, fatigue, aching muscles, fever and headache. Some people, however, are more likely to get flu complications that can result in hospitalization and sometimes death according to FDA. People at higher risk of developing influenza complications include Adults 65 years and older, pregnant women, young children, People who have chronic illnesses, such as asthma, heart disease, neurological condition and diabetes.
The main recommended treatment is OSELFLUE (IBN Hayyan Pharmaceuticals) with its active ingredient OSELTAMIVIR as an antiviral that treat and prevent influenza virus because:
OSELFLUE affects both types of virus A and B and therefore against a wide spectrum of infections.
OSELFLUE’s unique mechanism of action by inhibiting neuraminidase enzyme, which is essential in releasing the virus from the infected cell after replication.
OSELFLUE is used for children <1 and for pregnant women at risk of miscarriage.
OSELFLUE reduces the duration of illness about one and a half days, and reduces the severity of symptoms by 30%.
OSELFLUE is used prophylactically so, it reduces the risk of influenza by 55%, and protects from reuptake the disease again after recovery by 80%.
Hence the importance of using OSELFLUE in the treatment, prevention, and protection from infection.
Dosage and administration:
OSELFLUE may be taken with or without food.
For Treatment: Adult and adolescents: 75 mg twice daily for 5 days (Treatment should begin within 2 days of onset of symptoms of influenza).
For Prophylaxis: Adult and adolescents 75 mg once daily for 10 days (Therapy should begin within 2 days of exposure).
This article does not replace the doctor’s visit